Received Sep 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose back on twenty nineteen). On 05-SEP-2025, the patient received the 2nd dose of Shingrix. On 05-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 05-SEP-2025 The pharmacist called to ask about a patient vaccination schedule. The patient received a first dose of Shingrix back on twenty nineteen, and a second dose on 05th September 2025 which led to lengthening of vaccination schedule. The reporter asked was this patient ok with this timeframe, do they needed to revaccinate. No vaccine detail was obtained in this call. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.